Shareholders approve all proposals at annual general meeting – continued strong growth in Q1 2022

At today’s annual general meeting (AGM) of medmix Ltd, shareholders approved all proposals of the Board of Directors. Greg Poux-Guillaume was confirmed as Chairman, and Marco Musetti was re-elected. Additionally, Rob ten Hoedt, Daniel Flammer, Barbara Angehrn, René Willi and David Metzger were newly elected to the Board of Directors for a term until the end of the next AGM. medmix will pay an ordinary dividend of CHF 0.50 per share to shareholders. Revenue growth for Q1 at 11.9% YoY.

medmix’ shareholders approved all proposals of the company’s Board of Directors at its first AGM held in Winterthur, Switzerland. Due to the pandemic and in line with the COVID-19 Ordinance 3 of the Swiss Federal Council, shareholders were not allowed to attend the AGM in person. They were advised to authorize and instruct the independent proxy to cast their votes on their behalf. The independent proxy represented 77.03% of the share capital.

The shareholders approved the medmix Annual Report 2021, including the annual accounts and consolidated financial statements as well as the appropriation of the annual result. In addition, the shareholders approved medmix’ compensation report in a consultative vote.

An ordinary dividend of CHF 0.50 per share will be paid out on April 20, 2022. Discharge was granted to all members of the Board of Directors and the Executive Committee. The remuneration limits for the Board of Directors concerning the period from AGM 2022 to AGM 2023, and for the Executive Committee for the financial year 2023, were approved. KPMG was re-elected as auditor and Proxy Voting Services was also re-elected as the independent proxy.

Greg Poux-Guillaume was re-elected as member and Chairman of the Board of Directors, while Marco Musetti was also re-elected as member of the Board of Directors, both for a term until the end of the next AGM. Jill Lee did not stand for re-election. The Board of Directors thanks her for her valuable contribution to medmix’ spin-off and beginning as an independent company.

Rob ten Hoedt, Daniel Flammer, Barbara Angehrn, René Willi and David Metzger were elected for a term until the end of the next AGM as new members of the Board of Directors, bringing the total number of board members to seven. All new members have a background of international leadership and a diverse range of relevant experiences in medmix’ strategic focus markets. David Metzger and Daniel Flammer will represent Tiwel Holding AG, medmix’ principal shareholder.

Greg Poux-Guillaume, Rob ten Hoedt, and Barbara Angehrn were elected as members of the Remuneration Committee. After the AGM, the Board of Directors elected Marco Musetti as Vice Chairman of the Board and defined the new composition of the committees as follows:

• Audit Committee: Marco Musetti (Chairman), Daniel Flammer and René Willi
• Remuneration Committee: Rob ten Hoedt (Chairman), Greg Poux-Guillaume and Barbara Angehrn

The shareholders have also approved the relocation of medmix’ registered office from Zug to Baar and the corresponding change of the articles of association.

medmix continued its growth path in the first quarter of 2022. Revenue was up 19.5% above last quarter (Q4 2021) and year-over-year growth was at 11.9% (12.5% FX adjusted). Strong deliveries in the Healthcare business area are the main driver for the rise. The Consumer & Industry business area revenue also increased compared to last year and last quarter, but at a slower pace. medmix’ full year guidance for 2022 remains unchanged.

Business development activities remain on track despite the challenging market conditions. The company has taken an important step forward in its strategy to grow in Healthcare with the signing of a lease for a state-of-the-art production facility near Atlanta, GA (USA). Once operational, this hub will support all three Healthcare segments. Underlying its commitment to sustainable innovation, medmix continues to expand its portfolio of sustainable products with the launch of greenLineTM, for the Industry segment - reducing its customers environmental impact by 36%.

medmix is a global leader in high-precision delivery devices. We occupy leading positions in the healthcare, consumer and industrial end-markets. Our customers benefit from a dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 13 sites worldwide together with our highly motivated and experienced team of 1’900 employees provide our customers with uncompromising quality, proximity and agility. medmix is currently headquartered in Zug, Switzerland, and will soon relocate to Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX). www.medmix.swiss

This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.